U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18F3N3O2
Molecular Weight 377.3603
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LASMIDITAN

SMILES

CN1CCC(CC1)C(=O)C2=CC=CC(NC(=O)C3=C(F)C=C(F)C=C3F)=N2

InChI

InChIKey=XEDHVZKDSYZQBF-UHFFFAOYSA-N
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)

HIDE SMILES / InChI

Molecular Formula C19H18F3N3O2
Molecular Weight 377.3603
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.1 nM [Ki]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
526.15 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
LASMIDITAN plasma
Homo sapiens
population: healthy
age:
sex:
food status:
322.8 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
394.7 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3189.08 ng*h/mL
400 mg single, oral
dose: 400 mg
route of administration: oral
experiment type: single
co-administered:
LASMIDITAN plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1892 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2244 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LASMIDITAN serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
low
low
low
low
low
low
low
no (co-administration study)
Comment: "when administered with sumatriptan, no change in sumatriptan PK was observed; '""low potential of interactions"""
Page: 8, 18
no
no
no
no
no
no
no (co-administration study)
Comment: administered with caffeine, daily dosing of lasmiditan did not alter PK of caffeine
Page: 8.0
no
no (co-administration study)
Comment: administered with caffeine, daily dosing of lasmiditan did not alter PK of caffeine
Page: 8.0
no
no (co-administration study)
Comment: administered with tolbutamide, daily dosing of lasmiditan did not alter the PK of tolbutamide.
Page: 8.0
no
no (co-administration study)
Comment: administered with tolbutamide, daily dosing of lasmiditan did not alter the PK of tolbutamide.
Page: 8.0
no
no (co-administration study)
Comment: administered with midazolam, daily dosing of lasmiditan did not alter PK of midazolam
Page: 8.0
no
no (co-administration study)
Comment: administered with midazolam, daily dosing of lasmiditan did not alter PK of midazolam
Page: 8.0
yes [IC50 85 uM]
yes [Ki 20.7 uM]
yes
yes
yes
Drug as victimTox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
2010 Oct
Patents

Sample Use Guides

Lasmiditan in vitro binding studies show a Ki value of 2.21 nM at the 5-HT(1F) serotonin receptor, compared with Ki values of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively. Lasmiditan did not contract rabbit saphenous vein rings, a surrogate assay for human coronary artery constriction, at concentrations up to 100 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:35:00 GMT 2025
Edited
by admin
on Mon Mar 31 18:35:00 GMT 2025
Record UNII
760I9WM792
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LASMIDITAN
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
lasmiditan [INN]
Preferred Name English
Lasmiditan [WHO-DD]
Common Name English
2,4,6-Trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-2-yl}benzamide
Systematic Name English
COL-144
Code English
LASMIDITAN [MI]
Common Name English
LASMIDITAN [USAN]
Common Name English
Classification Tree Code System Code
DEA NO. 2790
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
Code System Code Type Description
FDA UNII
760I9WM792
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
INN
9176
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
WIKIPEDIA
LASMIDITAN
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
DAILYMED
760I9WM792
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
PUBCHEM
11610526
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
SMS_ID
100000172980
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
ChEMBL
CHEMBL3039520
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID40469435
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
MERCK INDEX
m12168
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
DRUG BANK
DB11732
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
DRUG CENTRAL
5351
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
USAN
ZZ-66
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
NCI_THESAURUS
C166996
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
LACTMED
Lasmiditan
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
RXCUI
2256930
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
CAS
439239-90-4
Created by admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
In vitro studies showed that lasmiditan is a substrate of P-gp. However, lasmiditan is a BCS Class I drug and is unlikely to be affected by P-gp inhibitors.
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
TRANSPORTER -> INHIBITOR
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
TRANSPORTER -> INHIBITOR
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
BINDER->LIGAND
The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION